New publication in The Lancet Respiratory Medicine
The Centre is pleased to be part of an international collaboration contributing to a new phase 3 randomised controlled trial examining bisoprolol use in people with moderately severe COPD.
Despite longstanding uncertainty around β-blocker therapy in COPD, this study found:
🔹 No improvement in cardiorespiratory outcomes
🔹 No difference in mortality, hospitalisations, exacerbations, lung function or quality of life
🔹 Bisoprolol was safe and well tolerated
These findings provide important clarity for clinical decision-making and future guideline discussions.
Read the article here
And the commentary here
